Merck stock trades firm as Keytruda growth supports guidance

Merck stock continues to be underpinned by expanding oncology revenue and steady Keytruda growth, while recent quarterly figures and guidance frame the current valuation on the NYSE.

Merck stock is currently supported by the company’s expanding oncology franchise, with Merck & Co., Inc. (ISIN US58933Y1055) generating multi-billion dollar revenue from cancer drug Keytruda in its latest reported quarter. In that quarter, Keytruda sales were reported at around $6.9 billion, reflecting a strong year-on-year increase and underpinning the group’s overall guidance for fiscal results. For investors, the scale and trajectory of this single product line now plays a central role in how Merck stock is valued on the NYSE.

Keytruda revenue tops billions

Oncology remains the core earnings driver for Merck & Co., Inc., and Keytruda has become one of the largest prescription medicines worldwide by revenue. In the most recently disclosed quarter, Merck indicated that Keytruda generated approximately $6.9 billion of sales, compared with a prior-period figure closer to $5.8 billion, marking an increase in the order of around 19% year on year. That acceleration highlights how the drug’s growing use across multiple cancer indications feeds directly into Merck’s consolidated revenue line and earnings power.

Beyond absolute revenue levels, the mix shift toward oncology has changed Merck’s margin profile. With specialty medicines typically commanding higher pricing and strong demand, Keytruda’s contribution supports a more profitable portfolio versus legacy primary care products. As Keytruda has moved deeper into earlier lines of treatment and more tumor types, the company’s reported numbers show a steady climb in oncology revenue share relative to other segments.

Total revenue and earnings trends

At the group level, Merck & Co., Inc. has reported quarterly revenue in the mid-$15 billion range, with recent figures indicating total sales around $15.8 billion versus roughly $14.5 billion a year earlier. That implies growth of close to 9% on a year-on-year basis, driven largely by oncology and vaccines. Such growth has helped offset patent-expiry pressure in other franchises and provides the foundation for Merck’s current guidance for the full fiscal year.

Earnings per share have also improved alongside revenue. In the latest quarter, Merck has reported adjusted EPS in the region of $2.07, up from about $1.40 in the prior-year quarter, indicating a jump of nearly 48% year on year. This combination of high-single-digit revenue growth and stronger EPS demonstrates operating leverage from the existing portfolio and disciplined cost control. For investors following Merck stock, the EPS trajectory is central to thinking about valuation multiples and how much growth is already reflected in the share price.

Management has paired these strong numbers with guidance that points to continued expansion, albeit at a more moderate pace as the base grows larger. Recent full-year guidance has suggested total revenue in a range between roughly $60 billion and $62 billion, implying mid-single- to high-single-digit growth over the previous year’s level. That guidance anchors expectations in the market and provides a reference point for analysts’ models.

Guidance and pipeline support

Merck’s guidance relies not only on Keytruda but also on a broader pipeline and existing portfolio across vaccines, hospital acute care, immunology, and animal health. The company’s human health segment includes vaccines such as Gardasil, which itself generated several billion dollars of annual revenue, and continues to benefit from expanded immunization programs. In a recent fiscal year, Gardasil sales were reported at close to $8 billion, up from roughly $5.7 billion the previous year, representing growth of around 40%. Such momentum in vaccines adds another pillar to Merck’s revenue base.

The pipeline is designed to sustain this growth beyond current blockbusters. Merck has invested heavily in oncology combinations, next-generation immunotherapies, and cardiometabolic drugs. The company’s R&D spend stands in the mid-teens as a percentage of sales, with annual R&D outlays in the region of $14 billion in a recent year on total revenue near $60 billion. This level of investment reflects management’s intention to maintain a deep pipeline and offset eventual patent expiries, particularly for Keytruda later in the decade.

For guidance, Merck’s management has indicated expectations of continued revenue growth from oncology and vaccines, tempered by pricing dynamics and competitive pressures. By coupling a substantial R&D commitment with partnerships and acquisitions, Merck aims to support mid-single-digit to high-single-digit revenue growth over the medium term. The market interprets this as a pathway toward sustained EPS expansion while maintaining dividend payments.

Dividend and cash flow profile

Merck’s capital allocation policy combines R&D investment with a steady dividend. In the latest fiscal year, Merck paid an annual dividend per share of around $3.00, up from approximately $2.76 in the previous year, reflecting a dividend increase of about 9%. That move aligns with the company’s growing earnings base and demonstrates management’s confidence in cash flow visibility. The dividend yield on Merck stock, calculated against recent share prices in the low $100s, typically falls in the range of roughly 2.5% to 3%.

Free cash flow has enabled this combination of shareholder returns and growth investment. Merck has reported annual operating cash flow above $20 billion, with free cash flow after capital expenditure exceeding $15 billion. These numbers provide Merck with the flexibility to fund R&D, maintain the dividend, and execute bolt-on acquisitions to bolster the pipeline. For investors, the cash flow profile is an important complement to the headline revenue and EPS figures.

The balance sheet is also structured to support this strategy. Merck carries a manageable level of net debt relative to EBITDA, often around two times, leaving room to absorb market volatility and regulatory changes in healthcare. The company’s credit ratings from major agencies sit in the high investment-grade area, reflecting stable earnings and predictable cash generation from diversified therapies.

Keytruda and oncology portfolio

Keytruda is approved for a broad range of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, renal cell carcinoma, and others. Over time, Merck has expanded its label through large-scale clinical trials, adding new indications and treatment lines. The reported $6.9 billion in quarterly sales underscores that the medicine has become a cornerstone of modern oncology regimens across many countries.

Merck’s strategy has been to test Keytruda in combination with other therapies, including chemotherapy, targeted therapies, and other immunotherapies. This has resulted in additional approvals and deeper penetration into the standard-of-care settings. As a result, the share of Merck’s total revenue derived from oncology has risen steadily, with oncology now accounting for well over one-third of group sales in recent reporting periods.

Investors in Merck stock closely monitor regulatory developments, such as new label extensions and approvals in major markets. Each approval not only adds potential revenue but can also extend Keytruda’s effective commercial life before generic competition. The scale of ongoing trials and the company’s track record of positive outcomes have contributed to the market’s confidence in continued oncology growth.

Gardasil and vaccine segment

Gardasil, Merck’s human papillomavirus (HPV) vaccine, has become another key revenue driver. With annual sales near $8 billion in the most recent fiscal year, up from around $5.7 billion the year before, its roughly 40% growth highlights strong demand from public health programs and private markets. This growth is driven by increased awareness of HPV-related cancers and broader immunization recommendations in multiple geographies.

The vaccines segment also includes other products that contribute to stable recurring revenue. Together, these therapies offer a diversified complement to oncology and reduce dependence on any single product. For Merck stock, the vaccines segment is often seen as providing a degree of resilience, as vaccination programs are frequently backed by government or institutional funding.

Merck continues to invest in next-generation vaccines and expanded indications, which could further enhance this revenue stream. The company’s established manufacturing and distribution network in vaccines provides scale advantages and supports margins.

Animal health and other businesses

Merck’s animal health division supplies pharmaceuticals and vaccines for livestock and companion animals. Annual revenue from this division is in the multi-billion-dollar range, often around $6 billion, providing a diversified income stream separate from human health. While not the primary focus for Merck stock investors, animal health contributes to revenue stability and offers exposure to global trends in protein consumption and pet care.

Animal health margins are supported by established brands and long product lifecycles. The division has benefited from innovations in parasiticides, vaccines, and monitoring technologies for livestock. These products offer a steady demand pattern, which is less sensitive to healthcare reimbursement dynamics that affect human pharmaceuticals.

In combination with human health, the animal health division helps to smooth out earnings across economic cycles. For Merck stock, this diversification can be relevant to risk assessment, especially when investors consider how exposed the company is to any single market or regulatory regime.

Regulatory and competitive landscape

Merck operates in a tightly regulated industry, and its products are subject to approval and ongoing oversight by agencies such as the US Food and Drug Administration and corresponding bodies worldwide. Regulatory approval processes, post-marketing surveillance, and pricing regulations all influence the company’s ability to commercialize new drugs and maintain margins.

The competitive landscape in oncology and vaccines is intense. Other large pharmaceutical companies are developing immunotherapies and targeted therapies that may compete with Keytruda, while rival vaccines can challenge Gardasil in certain markets. However, Merck’s current position with strong revenue numbers and broad approvals grants it a significant competitive moat, at least in the medium term.

Investors in Merck stock assess these regulatory and competitive factors alongside financial metrics. The scale of Merck’s operations and its R&D budget provide advantages in bringing new medicines to market and defending its franchises.

Valuation context for Merck stock

In equity markets, Merck stock is generally viewed as a large-cap pharmaceutical holding with a mix of growth and income characteristics. Market capitalization has recently stood in the range of approximately $260 billion to $280 billion, depending on share price movements. This size places Merck among the largest global healthcare companies and a significant constituent of major indices.

When valuing Merck stock, analysts often focus on the sustainability of Keytruda and Gardasil revenues, the pipeline’s ability to replace future expiries, and the steady dividend. Price-to-earnings multiples reflect expectations that oncology growth will moderate over time but remain positive, while vaccines and animal health provide additional support.

Merck’s presence in indices ensures that many institutional investors hold the stock as part of benchmark-driven portfolios. This can influence liquidity and trading dynamics, but the fundamental story remains anchored in the company’s financial performance and product portfolio.

Keytruda’s growth underpins Merck stock

Keytruda’s approximately $6.9 billion quarterly revenue, rising from about $5.8 billion a year earlier, encapsulates why oncology is so central to Merck’s current investment case. The nearly 19% year-on-year growth is not merely a one-off jump; it reflects a multi-year trend of expanding indications and wider clinical adoption. With oncology now representing well over one-third of Merck’s total revenue, this single product’s trajectory has an outsized impact on group earnings.

For Merck stock, this means that investors are effectively buying exposure to both current oncology cash flows and the future pipeline that aims to sustain them. If incremental trial data continue to support new approvals, Merck can potentially smooth the eventual transition when Keytruda’s patents expire. The strong revenue base also gives Merck the financial capacity to pursue acquisitions that complement its oncology portfolio.

At the same time, reliance on one major blockbuster introduces concentration risk that investors watch closely. Regulatory changes, competitive developments, or unexpected safety findings could alter Keytruda’s revenue profile. Merck’s strategy of investing heavily in diversified oncology assets and other therapeutic areas is designed to mitigate this risk.

Revenue up nearly 9 percent

Merck’s group revenue growth of around 9% year on year in its latest reported quarter, moving from roughly $14.5 billion to $15.8 billion, demonstrates that the company is able to grow from an already large base. This pace of expansion is meaningful for a firm of Merck’s scale and suggests that new products and indications are contributing alongside established franchises.

The revenue increase is particularly notable because it comes at a time when pricing pressure is a frequent topic in the pharmaceutical sector. Merck’s performance implies that volume growth and mix shifts toward higher-value therapies can offset such headwinds. In this context, the company’s investments in R&D and its focus on innovation are directly tied to financial outcomes.

Investors evaluating Merck stock often compare this growth rate with peers. A high-single-digit revenue increase for a large pharmaceutical group stands out, especially when backed by solid EPS growth and a growing dividend. This combination can be attractive for portfolios seeking both income and moderate growth.

Product focus: Keytruda

Keytruda is the centerpiece of Merck’s oncology strategy and a major contributor to revenue and earnings. In the most recent quarter, Merck reported Keytruda sales of about $6.9 billion, up from nearly $5.8 billion a year earlier, reflecting almost 19% growth. These figures underscore how the medicine’s use across multiple cancers has scaled rapidly from its early launch years.

The drug is administered as an infusion and works by targeting the PD-1 pathway to help the immune system recognize and attack cancer cells. Its broad set of indications means that Keytruda is used in many different clinical settings, from early-stage to advanced cancers. This breadth supports both high absolute revenue and resilience across tumor types.

For Merck, Keytruda’s success has validated its focus on immuno-oncology and shaped subsequent R&D investments. The company has pursued trials that test Keytruda as a backbone therapy in combination with other agents, aiming to maintain leadership in this area even as competition intensifies.

Merck stock and NYSE trading

Merck stock is listed on the NYSE under the ticker MRK and forms part of major US equity indices. Shares have in recent months traded in a band between roughly $100 and $130, with recent levels often around the middle of that range. At a share price near $115, Merck’s market capitalization would sit close to $270 billion, illustrating the company’s scale in global healthcare.

Daily trading volumes for Merck stock are typically high, reflecting its role as a core holding for many institutional and retail investors. Liquidity allows for efficient entry and exit, but price moves remain tied to earnings reports, clinical data releases, regulatory decisions, and broader market sentiment toward defensive sectors such as healthcare.

Merck’s combination of a substantial dividend, robust cash flow, and growth from oncology and vaccines shapes how investors perceive the risk and reward of holding the stock. While it is not a high-growth technology name, Merck offers a blend of income and moderate growth from a diversified pharmaceutical portfolio.

Merck & Co. stock facts

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: NYSE: MRK
• Trading venue: NYSE
• Price (as of 17 July 2026, 16:00 EST): 115.00 USD
• Market capitalization: 270,000,000,000 USD (as of 17 July 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 30 July 2026